Company intelligence / Profile preview

Theralase Technologies Inc.

Ownership: Public · TLT
Development stage: Phase 2

Overview

Theralase has reported positive Phase II data in BCG-unresponsive NMIBC with a 58% complete response at 90 days and 35% at 450 days using its Ruvidar PDC plus TLC‑3200 laser system. Over 80% of patients remained in the study after 90 days. The company has submitted pre-Breakthrough Designation updates to the FDA. For CLT devices targeting knee pain and other indications, products are Health Canada/FDA approved with ongoing expansion into new indications such as Parkinson’s disease motor/non-motor symptom improvement

Therapeutic areas: OncologyRheumatologyNeurology
Modalities: Photo Dynamic Compounds (PDCs)medical laser systems
Industry: Biotech

Drug pipeline

4 assets

TLD-1433

3 more assets in the full pipeline.

Request access →

Partnerships

In-license of PDC technology from Virginia Polytechnic Institute & State University ("Virginia Tech")academic collaborations with University of Windsor on clinical studies

Financials

Market cap: $41.3B
Enterprise value: $41.3B

Beyond the preview

Go deeper on Theralase Technologies Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theralase Technologies Inc..

Explore the full profile